Abstract

The majority of high-grade serous ovarian cancers (HGSCs) are deficient in homologous recombination (HR) DNA repair, most commonly due to mutations or hypermethylation of the BRCA1/2 genes. We aimed to discover how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor microenvironment. Using a highly multiplex immunofluorescence and image analysis we generate spatial proteomic data for 21 markers in 124,623 single cells from 112 tumor cores originating from 31 tumors with BRCA1/2 mutation (BRCA1/2mut), and from 13 tumors without alterations in HR genes. We identify a phenotypically distinct tumor microenvironment in the BRCA1/2mut tumors with evidence of increased immunosurveillance. Importantly, we report a prognostic role of a proliferative tumor-cell subpopulation, which associates with enhanced spatial tumor-immune interactions by CD8+ and CD4 + T-cells in the BRCA1/2mut tumors. The single-cell spatial landscapes indicate distinct patterns of spatial immunosurveillance with the potential to improve immunotherapeutic strategies and patient stratification in HGSC.

The tumour microenvironment has not been fully characterised in high-grade serous ovarian cancers (HGSOC). Here, the authors use highly multiplexed imaging to analyse the HGSOC immune microenvironment at spatial and single-cell resolution, with clinically relevant findings for BRCA1/2-mutated tumours.

Details

Title
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
Author
I-M, Launonen 1   VIAFID ORCID Logo  ; Lyytikäinen, N 1 ; Casado, J 1   VIAFID ORCID Logo  ; Anttila, E A 1   VIAFID ORCID Logo  ; Szabó, A 1 ; U-M, Haltia 2 ; Jacobson, C A 3   VIAFID ORCID Logo  ; Lin, J R 3 ; Maliga, Z 3 ; Howitt, B E 4 ; Strickland, K C 5 ; Santagata, S 6   VIAFID ORCID Logo  ; Elias, K 7 ; D’Andrea A D 8   VIAFID ORCID Logo  ; Konstantinopoulos, P A 8   VIAFID ORCID Logo  ; Sorger, P K 9   VIAFID ORCID Logo  ; Färkkilä, A 10   VIAFID ORCID Logo 

 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071) 
 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666) 
 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Stanford University School of Medicine, Department of Pathology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Duke University Medical Center, Department of Pathology, Durham, USA (GRID:grid.189509.c) (ISNI:0000000100241216) 
 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Department of Pathology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard Medical School, Ludwig Center for Cancer Research at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Brigham and Women’s Hospital, Department of Obstetrics and Gynecology and Reproductive Biology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Ludwig Center for Cancer Research at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
10  University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland (GRID:grid.38142.3c) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2627871758
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.